



US007029712B1

(12) **United States Patent**
Thornton et al.

(10) **Patent No.:** **US 7,029,712 B1**
(45) **Date of Patent:** **Apr. 18, 2006**

(54) **TREATMENT FOR DRY EYE SYNDROME**

(56) **References Cited**

(76) Inventors: **Spencer P. Thornton**, 5070 Villa Crest Dr., Nashville, TN (US) 37220; **Ellen Troyer**, 1 Mirada Rd., Colorado Springs, CO (US) 80906

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/521,067**

(22) PCT Filed: **Jul. 17, 2003**

(86) PCT No.: **PCT/US03/22297**

§ 371 (c)(1),
(2), (4) Date: **Jan. 11, 2005**

(87) PCT Pub. No.: **WO2004/006801**

PCT Pub. Date: **Jan. 22, 2004**

Related U.S. Application Data

(60) Provisional application No. 60/396,222, filed on Jul. 17, 2002.

(51) **Int. Cl.**

A61K 35/78 (2006.01)

A61K 35/60 (2006.01)

A61K 33/06 (2006.01)

A61K 31/355 (2006.01)

A61K 31/07 (2006.01)

(52) **U.S. Cl.** **424/756**; 424/776; 424/523;
424/682; 424/697

(58) **Field of Classification Search** None
See application file for complete search history.

U.S. PATENT DOCUMENTS

4,977,187 A * 12/1990 Horrobin 514/560
6,093,706 A 7/2000 Zeligs
6,316,465 B1 * 11/2001 Pershadsingh et al. 514/310
6,506,412 B1 1/2003 Troyer et al.
6,537,581 B1 3/2003 Tao
6,585,987 B1 7/2003 Frasoni
2002/0009505 A1 * 1/2002 Tao 424/725
2002/0128191 A1 9/2002 Scannon
2002/0188024 A1 * 12/2002 Chilton et al. 514/560

FOREIGN PATENT DOCUMENTS

JP 08040925 * 2/1996

OTHER PUBLICATIONS

Biswas et al. *Phytotherapy Res.* 2001. vol. 15, No. 7, pp. 618-620, EMBASE Abstract enclosed.*

* cited by examiner

Primary Examiner—Christopher R. Tate

(74) *Attorney, Agent, or Firm*—Sara A. Centioni; Michael A. Mann; Nexsen Pruet, LLC

(57) **ABSTRACT**

A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term “nutrient cofactor” refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.

20 Claims, 1 Drawing Sheet